BND-22

BND-22 is a first-in-class, humanized IgG4 monoclonal antibody that acts as an immune checkpoint inhibitor by selectively binding to and blocking the immunoglobulin-like transcript 2 (ILT2, also known as LILRB1) receptor. ILT2 is an inhibitory receptor expressed on both innate and adaptive immune cells—including T cells, natural killer (NK) cells, and myeloid cells—and interacts with major histocompatibility complex (MHC) class I molecules such as HLA-G. By blocking ILT2’s interaction with its ligands, BND-22 disrupts tumor-mediated “do not eat me” signals in macrophages and enhances the anti-tumor activity of NK and CD8+ T lymphocytes. This results in increased phagocytosis of tumor cells by macrophages, enhanced cytotoxicity of NK cells, improved T cell activation within the tumor microenvironment, and a broad antitumor immune response. Preclinical studies have shown robust antitumor effects in humanized mouse models. Clinical trials are ongoing for advanced solid tumors both as monotherapy (notably cholangiocarcinoma) and in combination with other agents such as cetuximab or pembrolizumab for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and ovarian cancer[1][2][3][5][6].

Other names

anti-ILT2 monoclonal antibodyanti-ILT-2 monoclonal antibodyanti-ILT 2 monoclonal antibodyanti-LILRB1 monoclonal antibodyanti-LILRB-1 monoclonal antibodyanti-LILRB 1 monoclonal antibody